← Back to Clinical Trials
Recruiting NCT05066139

NCT05066139 Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05066139
Status Recruiting
Phase
Sponsor Centre Paul Strauss
Condition Digestive System Disease
Study Type INTERVENTIONAL
Enrollment 144 participants
Start Date 2021-09-17
Primary Completion 2030-10-17

Eligibility & Interventions

Sex All sexes
Min Age 75 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
EPODIG-G program (coordination of supportive care)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 144 participants in total. It began in 2021-09-17 with a primary completion date of 2030-10-17.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a monocentric, comparative, open-label, randomized parallel group study enrolling elderly subjects hospitalized in Strasbourg Europe Cancerology Institute (ICANS), starting chemotherapy or targeted therapy for the treatment of digestive cancer.

Eligibility Criteria

Inclusion Criteria: * Patients must be ≥ 75 years old * Performance status 0, 1 or 2 * Diagnostic of digestive cancer, all stages (adjuvant or metastatic), with an indication for chemotherapy treatment or targeted therapy for a treatment period of 24 weeks or more * Patients previously treated with one or several lines of chemotherapy for this digestive cancer are eligible * Estimated life expectancy ≥ 3 months * Patients able to speak, read and understand French * Signed informed consent from the patient * Patients must have a social security coverage Exclusion Criteria: * History of differentiated neuroendocrine tumors grade 1 or 2 (pancreas, small intestine) * Cancer currently being treated (except for hormone therapy) other than current digestive cancer * History of major surgery and/or curative radiation therapy during the last 4 weeks before inclusion * Patients unable to submit to medical follow-up for geographical, social or psychological reasons * Patients placed under guardianship

Contact & Investigator

Central Contact

Valérie SARTORI

✉ v.sartori@icans.eu

📞 368767223

Frequently Asked Questions

Who can join the NCT05066139 clinical trial?

This trial is open to participants of all sexes, aged 75 Years or older, studying Digestive System Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05066139 currently recruiting?

Yes, NCT05066139 is actively recruiting participants. Contact the research team at v.sartori@icans.eu for enrollment information.

Where is the NCT05066139 trial being conducted?

This trial is being conducted at Strasbourg, France.

Who is sponsoring the NCT05066139 clinical trial?

NCT05066139 is sponsored by Centre Paul Strauss. The trial plans to enroll 144 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology